Fourth-generation accommodating IOL gets FDA ok
The fourth-generation Crystalens HD (Bausch & Lomb) accommodating intraocular lens (IOL) has received FDA marketing approval, five years after the lens was initially launched on the market.
The fourth-generation Crystalens HD (Bausch & Lomb) accommodating intraocular lens (IOL) has received FDA marketing approval, five years after the lens was initially launched on the market. The newest generation of the Crystalens provides an increased depth of focus without creating any additional dysphotopsia, thereby enhancing the near vision and maintaining the intermediate and distance vision improvement offered by the third-generation lens.
John Hovanesian, MD, FACS of the Jules Stein Eye Institute, UCLA, California, US and colleagues implanted the lens, using the same surgical protocol as with previous versions of the Crystalens, into eyes (n=125) with visually significant cataract combined with astigmatism of
Bausch & Lomb has now begun shipping of the fourth-generation Crystalens HD.
